Ziphius Vaccines

Ziphius Vaccines is an emerging biotech developing a proprietary self-amplifying RNA (saRNA) platform coupled with in-house lipid nanoparticle (LNP) delivery systems. The company leverages this technology to create a pipeline targeting infectious diseases, rare diseases, and oncology, aiming for potent, durable effects at lower doses than conventional mRNA. As a private, pre-clinical stage company, Ziphius is building its scientific team and platform capabilities to position itself in the competitive next-generation RNA therapeutics space.

Proprietary self-amplifying RNA (saRNA) platform coupled with an in-house library of lipid nanoparticles (LNPs) designed for saRNA delivery. The saRNA technology replicates within cells, enabling high, sustained protein expression at low doses.

Ziphius competes in the next-generation RNA space against large players like Moderna and BioNTech (which have saRNA programs) and numerous other biotechs (e.g., Arcturus, Replicate Bioscience, Gritstone bio). Differentiation hinges on demonstrating superior LNP delivery, optimized saRNA design, and compelling pre-clinical data.